Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
Submitted by
admin
on July 12, 2016 - 7:03pm
Source:
Investors.com
News Tags:
FDA
advisory panels
Amgen
biosimilars
Humira
ABP 501
Headline:
FDA Panel Resoundingly Backs Amgen's Biosimilar Humira
Do Not Allow Advertisers to Use My Personal information
